Aspira

PRISM MarketView Launches Emerging Women’s Health Index

Retrieved on: 
Thursday, January 4, 2024

NEW YORK, Jan. 04, 2024 (GLOBE NEWSWIRE) -- PRISM MarketView, a leading provider of unbiased market insight and company news, today announces the launch of its PRISM Emerging Women’s Health Index. The growth of the women’s health market is accelerating with the introduction of next-generation therapeutics and artificial intelligence (AI) powered imaging and diagnostics tools. The PRISM index tracks emerging companies delivering innovative solutions to address women’s health issues.

Key Points: 
  • NEW YORK, Jan. 04, 2024 (GLOBE NEWSWIRE) -- PRISM MarketView, a leading provider of unbiased market insight and company news, today announces the launch of its PRISM Emerging Women’s Health Index .
  • The PRISM index tracks emerging companies delivering innovative solutions to address women’s health issues.
  • PRISM Emerging Women’s Health Index outperformers this week include Minerva Surgical , which is up 12.63% in morning trading on Thursday, Sera Prognostics which has risen 6.90% and Agile Therapeutics which has gained 1.84%
    PRISM MarketView reviewed a selection of the companies set to transform the women’s health landscape in 2024.
  • Aspira Women's Health is dedicated to transforming women's health, starting with ovarian cancer.

Aspira Women’s Health Reports Third Quarter 2023 Financial Results

Retrieved on: 
Monday, November 13, 2023

AUSTIN, Texas, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Aspira Women’s Health Inc. (“Aspira”) (Nasdaq: AWH), a bio-analytical based women’s health company focused on the development of gynecologic disease diagnostic tools, today reported its financial results for the three- and nine-month period ended September 30, 2023.

Key Points: 
  • “We are pleased to report another quarter of year-over-year growth, with revenues this quarter of $2.2 million.
  • The Company expects general and administrative expenses to remain flat for the fourth quarter of 2023.
  • Our cash balance this quarter benefited from the registered direct offering where we raised $4.7 million in gross proceeds.
  • The Company reiterates its operating cash utilization target for the second half of 2023 to between $6.0 million and $8.0 million.

Aspira Women’s Health Supports Centers for Medicare & Medicaid Services (CMS) Proposed Rule to Crosswalk Medicare Reimbursement Rate for OvaWatch

Retrieved on: 
Thursday, November 9, 2023

AUSTIN, Texas, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Aspira Women’s Health Inc. (“Aspira” or “the Company”) (Nasdaq: AWH), a bio-analytical company focused on the development and commercialization of women’s health diagnostic tools for gynecologic diseases, today announced that during the 2024 Clinical Laboratory Fee Schedule (CLFS) rate setting process, the Centers for Medicare & Medicaid Services (CMS) has proposed to crosswalk the fee paid to the company for OvaWatch to the fee paid historically for Ova1. If finalized later this month (as was preliminarily approved in September), Aspira would be reimbursed at a rate of $897 for all OvaWatch and Ova1 tests processed for Medicare patients meeting applicable coverage requirements beginning in January 2024. The public comment period ended on October 27.

Key Points: 
  • If finalized later this month (as was preliminarily approved in September), Aspira would be reimbursed at a rate of $897 for all OvaWatch and Ova1 tests processed for Medicare patients meeting applicable coverage requirements beginning in January 2024.
  • “Crosswalking” refers to a process for setting the Medicare reimbursement rate for a new laboratory test by assigning the new code the same rate as a comparable existing test.
  • Aspira supports the proposal to crosswalk OvaWatch to Ova1 and believes it is appropriate given the similarity of pre-analytical, analytical, and post-analytical characteristics of the two assays.
  • “We are one step closer to achieving our mission of ensuring this ground-breaking technology is available to all women when they are facing an ovarian cancer diagnosis.”

Aspira Women’s Health Sees Poster on its miRNA-based Ovarian Cancer Test Presented at the AACR Special Conference in Cancer Research

Retrieved on: 
Wednesday, October 25, 2023

AUSTIN, Texas, Oct. 25, 2023 (GLOBE NEWSWIRE) -- Aspira Women’s Health Inc. (“Aspira” or “the Company”) (Nasdaq: AWH), a bio-analytical company focused on the development and commercialization of women’s health diagnostic tools for gynecologic diseases today announced that a poster on an in-development miRNA-based ovarian cancer test was presented at the AACR Special Conference in Cancer Research: Ovarian Cancer, held on October 5, 2023 in Boston, MA.

Key Points: 
  • AUSTIN, Texas, Oct. 25, 2023 (GLOBE NEWSWIRE) -- Aspira Women’s Health Inc. (“Aspira” or “the Company”) (Nasdaq: AWH), a bio-analytical company focused on the development and commercialization of women’s health diagnostic tools for gynecologic diseases today announced that a poster on an in-development miRNA-based ovarian cancer test was presented at the AACR Special Conference in Cancer Research: Ovarian Cancer, held on October 5, 2023 in Boston, MA.
  • The poster, entitled: “Improving the diagnostic accuracy of an ovarian cancer triage test using a joint miRNA-protein model,” highlighted data showing miRNA’s potential to improve the diagnostic accuracy of non-invasive diagnostic tests.
  • The study combined serum protein and patient clinical information (metadata) from Aspria’s ovarian cancer registry studies with miRNA determined by the Elias laboratory.
  • The analysis shows the potential for improving ovarian cancer diagnostics by combining our trusted technology with miRNA.

Aspira Announces the 2023 America’s State Parks Photo Contest Winners

Retrieved on: 
Friday, October 6, 2023

Aspira® in partnership with National Association of State Park Directors ( NASPD ) is proud to announce the winners of the seventh annual America’s State Parks Photo Contest.

Key Points: 
  • Aspira® in partnership with National Association of State Park Directors ( NASPD ) is proud to announce the winners of the seventh annual America’s State Parks Photo Contest.
  • Qualifying submissions were judged based on originality, artistic composition, technical quality, and whether the photograph showcases the best of America's State Parks camping and outdoor activities.
  • “Aspira is proud to give back to America’s State Parks and sponsor the photo contest for the seventh year in a row.
  • Partnering with America’s State Parks on the photo contest ensures that everyone can be involved in capturing the beauty of our State Parks.

Aspira Women’s Health Announces Dr. Jody Berry as New Chief Scientific Officer

Retrieved on: 
Monday, September 11, 2023

AUSTIN, Texas, Sept. 11, 2023 (GLOBE NEWSWIRE) -- Aspira Women’s Health Inc. (“Aspira” or “the Company”) (Nasdaq: AWH), a bio-analytical company focused on the development and commercialization of women’s health diagnostic tools for gynecologic diseases, today announced it has named Jody Berry, Ph.D. as its new Chief Scientific Officer.

Key Points: 
  • AUSTIN, Texas, Sept. 11, 2023 (GLOBE NEWSWIRE) -- Aspira Women’s Health Inc. (“Aspira” or “the Company”) (Nasdaq: AWH), a bio-analytical company focused on the development and commercialization of women’s health diagnostic tools for gynecologic diseases, today announced it has named Jody Berry, Ph.D. as its new Chief Scientific Officer.
  • Dr. Berry is a seasoned scientific leader with over two decades of commercial, government and academic experience.
  • Jody is a dynamic leader with decades of experience launching disruptive products and building effective research and development teams,” said Nicole Sandford, Chief Executive Officer of Aspira.
  • Dr. Berry is author or co-author on over 100 peer-reviewed published journal articles, abstracts, scientific posters, and monographs.

Merit Medical Launches the Aspira® Evacuated Drainage Bottle 

Retrieved on: 
Wednesday, September 6, 2023

SOUTH JORDAN, Utah, Sept. 06, 2023 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ: MMSI), a leading global manufacturer and marketer of healthcare technology, today announced U.S. commercial release of its Aspira Bottle.

Key Points: 
  • SOUTH JORDAN, Utah, Sept. 06, 2023 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ: MMSI), a leading global manufacturer and marketer of healthcare technology, today announced U.S. commercial release of its Aspira Bottle.
  • The new evacuated drainage bottle is the latest addition to Merit’s drainage portfolio.
  • The bottle also offers convenience with its ease-of-use and advanced design that requires 23% less storage space than the leading drainage bottle on the market.1 To further optimize patient comfort, the Aspira Bottle allows users to control drainage speed, helping to minimize discomfort and pain associated with high vacuum pressure drainage.
  • “The Aspira Bottle is one more way Merit strives to improve patient care, which includes providing the option of at-home care,” said Fred P. Lampropoulos, Merit Medical’s Chairman and CEO.

Aspira Women’s Health Signs Exclusive Sample Procurement Agreement with The University of Oxford

Retrieved on: 
Thursday, August 31, 2023

AUSTIN, Texas, Aug. 31, 2023 (GLOBE NEWSWIRE) -- Aspira Women’s Health Inc. (“Aspira” or “the Company”) (Nasdaq: AWH), a bio-analytical based diagnostic company focused on gynecologic health, today announced a material transfer agreement with The University of Oxford for the procurement of serum samples to be used to verify and validate the Company’s endometriosis blood test algorithms. Aspira expects to use the samples to support the launch of EndoCheckSM, its first-generation blood test to aid in the diagnosis of endometriosis, by the end of 2023.

Key Points: 
  • AUSTIN, Texas, Aug. 31, 2023 (GLOBE NEWSWIRE) -- Aspira Women’s Health Inc. (“Aspira” or “the Company”) (Nasdaq: AWH), a bio-analytical based diagnostic company focused on gynecologic health, today announced a material transfer agreement with The University of Oxford for the procurement of serum samples to be used to verify and validate the Company’s endometriosis blood test algorithms.
  • Aspira expects to use the samples to support the launch of EndoCheckSM, its first-generation blood test to aid in the diagnosis of endometriosis, by the end of 2023.
  • “We are excited to enter into this agreement with The University of Oxford.
  • We are excited to support Aspira Women’s Health in developing a much-needed test for the identification of this debilitating disease.”

Aspira Women’s Health Announces Michelle Snider as Senior Vice President, Commercial Strategy and Operations

Retrieved on: 
Monday, August 28, 2023

AUSTIN, Texas, Aug. 28, 2023 (GLOBE NEWSWIRE) -- Aspira Women’s Health Inc.(“Aspira” or “the Company”) (Nasdaq: AWH), a bio-analytical company focused on the development of women’s health diagnostic tools for gynecologic diseases, today announced it has named Michelle Snider as Senior Vice President, Commercial Strategy and Operations.

Key Points: 
  • AUSTIN, Texas, Aug. 28, 2023 (GLOBE NEWSWIRE) -- Aspira Women’s Health Inc.(“Aspira” or “the Company”) (Nasdaq: AWH), a bio-analytical company focused on the development of women’s health diagnostic tools for gynecologic diseases, today announced it has named Michelle Snider as Senior Vice President, Commercial Strategy and Operations.
  • She joins Aspira from Sema4 Genomics where she served as Vice President of Market Enablement/Sales Strategy during the company’s extraordinary growth.
  • In this role, she was responsible for women’s health commercial strategy and oversaw its financial and operational performance.
  • “Michelle has experience successfully launching new products as well as accelerating commercial growth for more mature offerings.

Aspira Women’s Health® Reports Second Quarter 2023 Financial Results

Retrieved on: 
Monday, August 14, 2023

AUSTIN, Texas, Aug. 14, 2023 (GLOBE NEWSWIRE) -- Aspira Women’s Health Inc. (“Aspira”) (Nasdaq: AWH), a bio-analytical based women’s health company focused on the development of gynecologic disease diagnostic tools, today reported its financial results for the second quarter ended June 30, 2023.

Key Points: 
  • Continued growth trend with second quarter revenue of $2.5 million, an increase of 23% over the second quarter of 2022.
  • OvaSuiteSM volume of 6,289 units, an increase of 16% year-over-year
    Achieved cash used in operations of $3.4 million, a decrease of 46% compared to the second quarter of 2022
    AUSTIN, Texas, Aug. 14, 2023 (GLOBE NEWSWIRE) -- Aspira Women’s Health Inc. (“Aspira”) (Nasdaq: AWH), a bio-analytical based women’s health company focused on the development of gynecologic disease diagnostic tools, today reported its financial results for the second quarter ended June 30, 2023.
  • OvaWatchSM test volume grew 80% in its second full quarter, contributing 14% of the total 6,289 OvaSuite tests performed.
  • Reduced cash used in operations to $3.4 million in the second quarter of 2023, compared to $6.3 million in the second quarter of 2022, a reduction of 46% year-over-year.